Sakhee Kotecha1, Jamie Hobson2, Jeremy Fuller2, Eldho Paul3, Bronwyn J Levvey2, Helen Whitford2, Miranda Paraskeva2, David McGiffin4, Gregory I Snell2, Glen P Westall2. 1. Lung Transplant Service, Alfred Hospital, Melbourne, Australia. Electronic address: s.kotecha@alfred.org.au. 2. Lung Transplant Service, Alfred Hospital, Melbourne, Australia. 3. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; Department of Haematology, Alfred Hospital, Melbourne, Australia. 4. Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia.
Abstract
BACKGROUND: In an era of increasing ex vivo lung perfusion (EVLP) use, it remains important to describe what outcomes can be achieved without EVLP, by taking an aggressive approach to donor use to maximize lung transplantation. METHODS: Data for all lung transplant donor referrals to the Alfred Hospital in Melbourne, Australia were collected for 2012 to 2013. Donor variables were analyzed and calculated into a previously validated lung donor score. Lung transplant recipient outcome data included the following: primary graft dysfunction; duration of mechanical ventilation; need for cardiopulmonary bypass extracorporeal membrane oxygenation; intensive care and hospital length of stay; 30-day, 1-year, and 3- to 4-year survival rates; rates of acute rejection and chronic lung allograft dysfunction; and peak and 12-month lung function (forced expiratory volume in 1 second). RESULTS: Of the 318 lung donor offers, 129 resulted in successful lung transplantation, with an overall donor use rate of 41%. There was no correlation between donor score and any of the recipient outcomes, and excellent short-term and longer-term survival was achieved. CONCLUSIONS: Future studies examining lung transplantation outcomes with EVLP must consider the excellent results that can be achieved by using marginal lungs and conventional donor management. It is important to consider that adopting a strategy of perioperative lung donor evaluation and intervention allows use of what are considered marginal lungs to achieve promising results.
BACKGROUND: In an era of increasing ex vivo lung perfusion (EVLP) use, it remains important to describe what outcomes can be achieved without EVLP, by taking an aggressive approach to donor use to maximize lung transplantation. METHODS: Data for all lung transplant donor referrals to the Alfred Hospital in Melbourne, Australia were collected for 2012 to 2013. Donor variables were analyzed and calculated into a previously validated lung donor score. Lung transplant recipient outcome data included the following: primary graft dysfunction; duration of mechanical ventilation; need for cardiopulmonary bypass extracorporeal membrane oxygenation; intensive care and hospital length of stay; 30-day, 1-year, and 3- to 4-year survival rates; rates of acute rejection and chronic lung allograft dysfunction; and peak and 12-month lung function (forced expiratory volume in 1 second). RESULTS: Of the 318 lung donor offers, 129 resulted in successful lung transplantation, with an overall donor use rate of 41%. There was no correlation between donor score and any of the recipient outcomes, and excellent short-term and longer-term survival was achieved. CONCLUSIONS: Future studies examining lung transplantation outcomes with EVLP must consider the excellent results that can be achieved by using marginal lungs and conventional donor management. It is important to consider that adopting a strategy of perioperative lung donor evaluation and intervention allows use of what are considered marginal lungs to achieve promising results.
Authors: Marco Schiavon; Giulio Faggi; Lorenzo Rosso; Luca Luzzi; Giovanni Maria Comacchio; Dario Gregori; Mario Nosotti; Francesco Damarco; Andrea Dell'Amore; David Bennet; Antonella Fossi; Piero Paladini; Luigi Santambrogio; Federico Rea Journal: J Thorac Dis Date: 2019-11 Impact factor: 2.895
Authors: Max T Buchko; Nasim Boroumand; Jeffrey C Cheng; Alim Hirji; Kieran Halloran; Darren H Freed; Jayan Nagendran Journal: Nat Commun Date: 2020-11-13 Impact factor: 14.919
Authors: Samantha E Halpern; Oliver K Jawitz; Vignesh Raman; Ashley Y Choi; John C Haney; Jacob A Klapper; Matthew G Hartwig Journal: Clin Transplant Date: 2021-07-14 Impact factor: 3.456